Cytochrome c Oxidase I (MT-CO1) is a mitochondrial DNA-encoded protein that forms the core catalytic subunit of Complex IV (Cytochrome c oxidase) in the electron transport chain. It is essential for aerobic energy production and has been implicated in various neurodegenerative diseases.
| Cytochrome c Oxidase I (MT-CO1) |
|---|
| Gene | [MT-CO1](/genes/mt-co1) (mitochondrial) |
| UniProt | [P00395](https://www.uniprot.org/uniprot/P00395) |
| Molecular Weight | ~57 kDa |
| Subcellular Localization | Mitochondrial inner membrane |
| Protein Family | Cytochrome c oxidase subunit 1 family |
MT-CO1 is the largest subunit of Complex IV and contains the catalytic core for oxygen reduction:
- Catalytic Activity: Binds and reduces molecular oxygen to water
- Electron Transfer: Receives electrons from cytochrome c
- Proton Pumping: Pumps protons across the inner membrane
- Heme a and CuA Centers: Contains the redox centers for electron transfer
- Highly expressed in neurons, especially in high-energy regions
- Critical for synaptic function and neuronal survival
- Mutations cause severe encephalopathies
- Complex IV deficiency is observed in AD brain tissue
- MT-CO1 mutations may accelerate amyloid pathology
- Reduced cytochrome c oxidase activity impairs neuronal metabolism
- Complex IV dysfunction contributes to PD pathogenesis
- MT-CO1 variants have been linked to PD risk
- Alpha-synuclein may inhibit Complex IV activity
- MT-CO1 mutations cause classic Leigh syndrome
- Characterized by bilateral brainstem lesions
- Presents with rapid neurological deterioration
- Coenzyme Q10: May improve electron flow
- Dichloroacetate: Metabolic regulator
- Gene therapy: mtDNA delivery approaches
- Mitochondrial replacement therapy
- Small molecule Complex IV activators
- Antioxidant therapies targeting oxidative stress
- Cytochrome c oxidase in Alzheimer's disease (2020)
- MT-CO1 mutations and neurodegeneration (2019)
- Complex IV deficiency in Parkinson's disease (2021)